Pivotal single dose 3-way bioequivalence study of ELI 202 under fasting and fed conditions in volunteers.

Trial Profile

Pivotal single dose 3-way bioequivalence study of ELI 202 under fasting and fed conditions in volunteers.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 May 2014

At a glance

  • Drugs ELI 202 (Primary)
  • Indications Opioid abuse; Pain
  • Focus Pharmacokinetics; Registrational
  • Sponsors Elite Pharmaceuticals
  • Most Recent Events

    • 26 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top